A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.

Trial Details

NCT ID
NCT05536141
Phase
PHASE1
Sponsor
Arcus Biosciences, Inc.
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • casdatifan
  • Cabozantinib
  • Zimberelimab
  • Ipilimumab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • San Diego, California, United States|32.71571,-117.16472
  • Santa Monica, California, United States|34.01949,-118.49138
  • Miami, Florida, United States|25.77427,-80.19366
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Must have at least one measurable lesion per RECIST guidance
  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1
  • Disease-specific criteria for dose escalation:
  • Participants may have any pathologically confirmed solid tumor type where no other treatment options are available

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →